Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring

Genome Biology

Volumn 8, Issue 11, 2007, Pages

  Wang, Xi De ^a   Reeves, Karen ^a   Luo, Feng R ^a   Xu, Li An ^a   Lee, Francis ^a   Clark, Edwin ^a   Huang, Fei ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 5; DASATINIB; EPHRIN A2; PROSTATE SPECIFIC ANTIGEN; UROKINASE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION FUNCTION; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC MARKER; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PATIENT SELECTION; PHARMACOGENETICS; PREDICTION; PROSTATE CANCER; GENETICS; MALE; METABOLISM; MONITORING; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PATIENT SELECTION; PROSTATIC NEOPLASMS; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 46349105930     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2007-8-11-r255     Document Type: Article

References (41)

1. Jemal A Siegel R Ward E Murray T Xu J Smigal C Thun MJ Cancer statistics, 2006. CA Cancer J Clin 2006 56 106-130 16514137
2. Denmeade SR Isaacs JT A history of prostate cancer treatment. Nat Rev Cancer 2002 2 389-396 10.1038/nrc801 12044015
3. Tannock IF de Wit R Berry WR Horti J Pluzanska A Chi KN Oudard S Theodore C James ND Turesson I et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 1502-1512 10.1056/NEJMoa040720 15470213
4. Pegram MD Lipton A Hayes DF Weber BL Baselga JM Tripathy D Baly D Baughman SA Twaddell T Glaspy JA et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998 16 2659-2671 9704716
5. Castro M The simpleton's error in drug development. J Clin Oncol 2002 20 4606-4607 10.1200/JCO.2002.99.183 12454124
6. Betensky RA Louis DN Cairncross JG Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002 20 2495-2499 10.1200/JCO.2002.06.140 12011127
7. Lombardo LJ Lee FY Chen P Norris D Barrish JC Behnia K Castaneda S Cornelius LA Das J Doweyko AM et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin- 1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
8. Huang F Reeves K Han X Fairchild C Platero S Wong TW Lee F Shaw P Clark E Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection. Cancer Res 2007 67 2226-2238 10.1158/0008-5472.CAN-06-3633 17332353
9. Shah NP Tran C Lee FY Chen P Norris D Sawyers CL Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 305 399-401 10.1126/science.1099480 15256671
10. Talpaz M Shah NP Kantarjian H Donato N Nicoll J Paquette R Cortes J O'Brien S Nicaise C Bleickardt E Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 354 2531-2541 10.1056/NEJMoa055229 16775234
11. Yeatman TJ A renaissance for SRC. Nat Rev Cancer 2004 4 470-480 10.1038/ nrc1366 15170449
12. Ishizawar R Parsons SJ c-Src and cooperating partners in human cancer. Cancer Cell 2004 6 209-214 10.1016/j.ccr.2004.09.001 15380511
13. Nam S Kim D Cheng JQ Zhang S Lee JH Buettner R Mirosevich J Lee FY Jove R Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005 65 9185-9189 10.1158/ 0008-5472.CAN-05-1731 16230377
14. Walker-Daniels J Coffman K Azimi M Rhim JS Bostwick DG Snyder P Kerns BJ Waters DJ Kinch MS Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999 41 275-280 10.1002/ (SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T 10544301
15. Bell SM Brackenbury RW Leslie ND Degen JL Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. J Biol Chem 1990 265 1333-1338 2153128
16. Singh D Febbo PG Ross K Jackson DG Manola J Ladd C Tamayo P Renshaw AA D'Amico AV Richie JP et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002 1 203-209 10.1016/ S1535-6108(02)00030-2 12086878
17. Marker PC Donjacour AA Dahiya R Cunha GR Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003 253 165-174 10.1016/S0012-1606(02)00031-3 12645922
18. Litvinov IV Vander Griend DJ Xu Y Antony L Dalrymple SL Isaacs JT Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006 66 8598-8607 10.1158/ 0008-5472.CAN-06-1228 16951173
19. Lin AM Rini BI Derynck MK Weinberg V Park M Ryan CJ Rosenberg JE Bubley G Small EJ A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clinical genitourinary cancer 2007 5 323-328 17645829
20. Lin AM Rini BI Weinberg V Fong K Ryan CJ Rosenberg JE Fong L Small EJ A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international 2006 98 763-769 10.1111/j.1464-410X.2006.06396.x 16796694
21. Guo L Lobenhofer EK Wang C Shippy R Harris SC Zhang L Mei N Chen T Herman D Goodsaid FM et al. Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol 2006 24 1162-1169 10.1038/nbt1238 17061323
22. Goldenberg-Furmanov M Stein I Pikarsky E Rubin H Kasem S Wygoda M Weinstein I Reuveni H Ben-Sasson SA Lyn is a target gene for prostate cancer: Sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004 64 1058-1066 10.1158/0008-5472.CAN-03-2420 14871838
23. Finn RS Dering J Ginther C Wilson CA Glaspy P Tchekmedyian N Slamon DJ Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007 17268817
24. Charafe-Jauffret E Ginestier C Monville F Finetti P Adelaide J Cervera N Fekairi S Xerri L Jacquemier J Birnbaum D et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006 25 2273-2284 10.1038/sj.onc.1209254 16288205
25. Perou CM Sorlie T Eisen MB van de Rijn M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA et al. Molecular portraits of human breast tumours. Nature 2000 406 747-752 10.1038/35021093 10963602
26. Sorlie T Tibshirani R Parker J Hastie T Marron JS Nobel A Deng S Johnsen H Pesich R Geisler S et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003 100 8418-8423 166244 12829800 10.1073/pnas.0932692100
27. Lapointe J Li C Higgins JP van de Rijn M Bair E Montgomery K Ferrari M Egevad L Rayford W Bergerheim U et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004 101 811-816 321763 14711987 10.1073/pnas.0304146101
28. Abate-Shen C Shen MM Molecular genetics of prostate cancer. Genes Dev 2000 14 2410-2434 10.1101/gad.819500 11018010
29. Patrawala L Calhoun T Schneider-Broussard R Li H Bhatia B Tang S Reilly JG Chandra D Zhou J Claypool K et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006 25 1696-1708 10.1038/ sj.onc.1209327 16449977
30. van Bokhoven A Varella-Garcia M Korch C Johannes WU Smith EE Miller HL Nordeen SK Miller GJ Lucia MS Molecular characterization of human prostate carcinoma cell lines. Prostate 2003 57 205-225 10.1002/ pros.10290 14518029
31. Chen CD Welsbie DS Tran C Baek SH Chen R Vessella R Rosenfeld MG Sawyers CL Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004 10 33-39 10.1038/nm972 14702632
32. Guo Z Dai B Jiang T Xu K Xie Y Kim O Nesheiwat I Kong X Melamed J Handratta VD et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006 10 309-319 10.1016/j.ccr.2006.08.021 17045208
33. Cozzi PJ Wang J Delprado W Madigan MC Fairy S Russell PJ Li Y Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 2006 37 1442-1451 10.1016/ j.humpath.2006.05.002 16949925
34. Rocchi P Muracciole X Fina F Mulholland DJ Karsenty G Palmari J Ouafik L Bladou F Martin PM Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene 2004 23 9111-9119 10.1038/sj.onc.1208154 15489889
35. Pulukuri SM Gondi CS Lakka SS Jutla A Estes N Gujrati M Rao JS RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005 280 36529-36540 1351057 16127174 10.1074/jbc.M503111200
36. Miyake H Hara I Yamanaka K Arakawa S Kamidono S Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 1999 14 535-541 10024688
37. Shariat SF Roehrborn CG McConnell JD Park S Alam N Wheeler TM Slawin KM Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007 25 349-355 10.1200/JCO.2006.05.6853 17264329
38. Urban P Vuaroqueaux V Labuhn M Delorenzi M Wirapati P Wight E Senn HJ Benz C Eppenberger U Eppenberger-Castori S Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 2006 24 4245-4253 10.1200/JCO.2005.05.1912 16963728
39. Janicke F Prechtl A Thomssen C Harbeck N Meisner C Untch M Sweep CG Selbmann HK Graeff H Schmitt M Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001 93 913-920 10.1093/jnci/93.12.913 11416112
40. Thomas SM Brugge JS Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997 13 513-609 10.1146/annurev.cellbio.13.1.513 9442882
41. Eisen MB Spellman PT Brown PO Botstein D Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998 95 14863-14868 24541 9843981 10.1073/pnas.95.25.14863